Edition:
United Kingdom

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

2.92USD
8:02pm BST
Change (% chg)

$0.02 (+0.69%)
Prev Close
$2.90
Open
$2.88
Day's High
$2.97
Day's Low
$2.88
Volume
41,463
Avg. Vol
147,662
52-wk High
$4.51
52-wk Low
$2.20

Latest Key Developments (Source: Significant Developments)

Catalyst Pharmaceuticals Q2 GAAP Loss Per Share $0.06
Tuesday, 7 Aug 2018 

Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 GAAP LOSS PER SHARE $0.06.Q2 EARNINGS PER SHARE VIEW $-0.08 -- THOMSON REUTERS I/B/E/S.POTENTIAL LAUNCH OF FIRDAPSE FOR LEMS IN EARLY 2019.EXPECTS THAT COSTS RELATED TO RESEARCH AND DEVELOPMENT ACTIVITIES WILL CONTINUE TO BE SUBSTANTIAL THROUGHOUT 2018.CATALYST PHARMACEUTICALS - BELIEVES EXISTING CAPITAL RESOURCES WILL BE SUFFICIENT TO SUPPORT PLANNED OPERATIONS THROUGH 2019.  Full Article

Catalyst Pharma Submits NDA For Firdapse
Thursday, 29 Mar 2018 

March 29 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR FIRDAPSE® FOR TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME.CATALYST PHARMACEUTICALS - SUBMISSION OF NDA TO U.S. FDA FOR FIRDAPSE.  Full Article

Great Point Partners Reports 5.14 Pct Passive Stake In Catalyst Pharma
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Catalyst Pharmaceuticals Inc ::GREAT POINT PARTNERS LLC REPORTS A 5.14 PERCENT PASSIVE STAKE IN CATALYST PHARMACEUTICALS INC AS OF NOV 28 - SEC FILING.  Full Article

Catalyst Pharma Announces Proposed Public Offering Of Common Stock
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 11.0 MILLION COMMON SHARES.CATALYST-PLANS TO USE PROCEEDS TO FUND CLINICAL STUDIES OF FIRDAPSE FOR TREATMENT OF MUSK-ANTIBODY POSITIVE MYASTHENIA GRAVIS,SPINAL MUSCULAR ATROPHY​.- PLANS TO USE NET PROCEEDS FROM OFFERING TO FUND PRE-COMMERCIALIZATION ACTIVITIES FOR FIRDAPSE​.  Full Article

Catalyst Pharma Posts Positive Top-Line Results From Second Phase 3 Clinical Trial Of Firdapse
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM SECOND PHASE 3 CLINICAL TRIAL OF FIRDAPSE® IN PATIENTS WITH LAMBERT-EATON MYASTHENIC SYNDROME.CATALYST PHARMACEUTICALS INC - ‍TREATMENT WITH FIRDAPSE ACHIEVED STATISTICAL SIGNIFICANCE FOR CO-PRIMARY ENDPOINTS AND SECONDARY ENDPOINT​.CATALYST PHARMACEUTICALS INC - ‍POSITIVE RESULTS TO SUPPORT PLANNED NDA SUBMISSION IN Q1 OF 2018​.CATALYST PHARMACEUTICALS INC - ‍FIRDAPSE WAS SAFE AND WELL TOLERATED BY PATIENTS IN TRIAL​.  Full Article

Catalyst Pharmaceuticals posts Q3 loss per share $0.05
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Catalyst Pharmaceuticals Inc :Catalyst Pharmaceuticals announces third quarter 2017 financial results and provides corporate update.Q3 GAAP loss per share $0.05.Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.Catalyst Pharmaceuticals Inc - ‍expects pre-commercialization expenses to increase in Q4 of 2017​.  Full Article

Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse®
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Catalyst Pharmaceuticals Inc :Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse® in patients with Lambert-Eaton Myasthenic Syndrome.Catalyst Pharmaceuticals Inc - ‍top-line results for Phase 3 trial of Firdapse expected in early December​.  Full Article

BRIEF-Catalyst Pharmaceuticals Reports Q1 GAAP Loss Per Share $0.06

* CATALYST PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE